Kazia Therapeutics


AU$30m market cap

AU$0.32 last close

Kazia Therapeutics has two clinical stage anti-cancer drugs: GDC-0084 (targeting glioblastoma) and Cantrixil (targeting ovarian cancer). GDC-0084 was inlicensed from Genentech, and Kazia is seeking other in-licence opportunities.

Investment summary

Kazia Therapeutics has announced that GDC-0084, its promising glioblastoma drug, will join (subject to definitive agreement) the pivotal GBM AGILE trial. AGILE is a clinician-led trial that currently enables fast access to 11 US glioblastoma centers. GDC-0084 could be dosed from Q2/Q3 CY20. Data from the 20-patient stage of the GDC-0084 Phase II should be available during 2020. Our indicative value remains at $93m.

Y/E Jun
Revenue (A$m)
PBT (A$m)
EPS (c)
P/E (x)
P/CF (x)
2018A 2.9 (10.9) (11.0) (22.2) N/A N/A
2019A 1.5 (7.6) (7.7) (12.9) N/A N/A
2020E 1.5 (8.7) (8.7) (12.6) N/A N/A
2021E 1.5 (11.1) (11.1) (17.9) N/A N/A
Industry outlook

Kazia’s two drug technology platforms are GDC-0084, a PI3K inhibitor in-licensed from Genentech, and Cantrixil, an intra-peritoneal formulation of a novel cytotoxic drug. Kazia is recruiting a 20-patient expansion cohort in its current GDC-0084 Phase II. GDC-0844 is in five other Phase IIa studies.

Last updated on 20/06/2019
Share price graph
Balance sheet
Forecast net cash (A$m) 0.5
Forecast gearing ratio (%) N/A
Key management
Iain Ross Chairman
James Garner CEO

Content on Kazia Therapeutics